Ann Surg Oncol8 Jun 2025
A phase II clinical trial demonstrates the feasibility of mass-based response testing (MRT) in tailoring intraperitoneal chemotherapy for patients with unresectable appendiceal or colorectal peritoneal metastases. MRT assessed tumor susceptibility to various HIPEC drug regimens, offering a personalized approach to treatment. The study aims to…
Eur J Surg Oncol18 Apr 2025
A novel deep-learning model, known as DEAF, accurately predicts the completeness of cytoreductive surgery (CRS) in colorectal cancer patients with peritoneal metastasis. Achieving an area under the curve (AUC) of 0.9 in the internal validation cohort, and higher AUC values in three external cohorts, the…
Cytoreductive Surgery & Peritoneum21 Mar 2025
Elevated preoperative levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA125) in colorectal cancer patients with peritoneal metastases significantly influence overall survival. In a study of 204 patients, the presence of high CA19-9 and CA125 was linked to poorer outcomes,…
Cytoreductive Surgery & Peritoneum12 Mar 2025
Recent insights into gastric cancer with peritoneal metastasis (gcpm) reveal dismal outcomes, underscoring the need for improved management strategies. A growing body of clinical trials investigates the efficacy of cytoreductive surgery (crs) combined with hyperthermic intraperitoneal chemotherapy (hipec), recognized in new national guidelines. Enhanced understanding…
World J Surg Oncol5 Mar 2025
Findings indicate that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and intraoperative radiation therapy (IORT) significantly improves overall survival (63 months) and disease-free survival (87 months) for gastric cancer patients. Over one-third of participants experienced no postoperative complications, while those who did faced a…
World J Surg Oncol21 Feb 2025
A meta-analysis of seven studies involving 1,550 patients has pinpointed significant preoperative and intraoperative risk factors for acute kidney injury (AKI) after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Preoperative factors include age, sex, BMI, and diabetes, while intraoperative factors include low systolic blood…
Ann Surg Oncol7 Feb 2025
A machine-learning model, specifically the extreme gradient boost (XGBoost), was developed to predict postoperative infection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with splenectomy. The model demonstrated excellent prediction accuracy, achieving an area under the curve (AUC) of 0.910 in preliminary testing and 0.823 in…
Clin Exp Gastroenterol4 Feb 2025
Analysis reveals a strong correlation between tumor-stroma ratio (tsr) and peritoneal metastasis (pm) in gastric cancer patients. The study included 640 patients across several cohorts, establishing a diagnostic model integrating tsr with CA125, CA724, and Borrmann type. The model demonstrated robust predictive capabilities, achieving an…
Cytoreductive Surgery & Peritoneum2 Feb 2025
Clustering preoperative tumor marker patterns aids in predicting surgical outcomes for patients with peritoneal metastases. Among 138 with pseudomyxoma peritonei (pMP), two distinct clusters emerged—pMP cluster-1 had a 5-year overall survival rate of 77%, while pMP cluster-2 faced a significantly poorer prognosis of 36%. A…
J Gastrointest Surg17 Jan 2025
In patients with colorectal peritoneal metastases, cytoreductive surgery has shown significant survival benefits, regardless of the use of intraperitoneal chemotherapy. Despite recent challenges to the efficacy of intraperitoneal treatments, the comprehensive review indicates that surgical intervention remains a crucial component in managing this aggressive form…